Design, synthesis, and biological evaluation of small, high-affinity siglec-7 ligands: toward novel inhibitors of cancer immune evasion

Natural killer cells are able to directly lyse tumor cells, thereby participating in the immune surveillance against cancer. Unfortunately, many cancer cells use immune evasion strategies to avoid their eradication by the immune system. A prominent escape strategy of malignant cells is to camouflage...

Full description

Saved in:
Bibliographic Details
Main Authors: Prescher, Horst (Author) , Gütgemann, Stephan Alexander (Author) , Watzl, Carsten (Author) , Brossmer, Reinhard (Author)
Format: Article (Journal)
Language:English
Published: January 19, 2017
In: Journal of medicinal chemistry
Year: 2017, Volume: 60, Issue: 3, Pages: 941-956
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.6b01111
Online Access:Verlag, Volltext: http://dx.doi.org/10.1021/acs.jmedchem.6b01111
Verlag, Volltext: https://doi.org/10.1021/acs.jmedchem.6b01111
Get full text
Author Notes:Horst Prescher, Martin Frank, Stephan Gütgemann, Elena Kuhfeldt, Astrid Schweizer, Lars Nitschke, Carsten Watzl, and Reinhard Brossmer
Description
Summary:Natural killer cells are able to directly lyse tumor cells, thereby participating in the immune surveillance against cancer. Unfortunately, many cancer cells use immune evasion strategies to avoid their eradication by the immune system. A prominent escape strategy of malignant cells is to camouflage themselves with Siglec-7 ligands, thereby recruiting the inhibitory receptor Siglec-7 expressed on the NK cell surface which subsequently inhibits NK-cell-mediated lysis. Here we describe the synthesis and evaluation of the first, high-affinity low molecular weight Siglec-7 ligands to interfere with cancer cell immune evasion. The compounds are Sialic acid derivatives and bind with low micromolar Kd values to Siglec-7. They display up to a 5000-fold enhanced affinity over the unmodified sialic acid scaffold αMe Neu5Ac, the smallest known natural Siglec-7 ligand. Our results provide a novel immuno-oncology strategy employing natural immunity in the fight against cancers, in particular blocking Siglec-7 with low molecular weight compounds.
Item Description:Gesehen am 24.09.2018
Physical Description:Online Resource
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.6b01111